Pliant Therapeutics, Inc.
PLRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.02 | -0.03 | 0.29 |
| FCF Yield | -23.20% | -57.18% | -59.44% | -6.00% |
| EV / EBITDA | -0.94 | -0.34 | -0.93 | -16.23 |
| Quality | ||||
| ROIC | -10.87% | -16.19% | -18.57% | -14.64% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.80 | 0.94 | 0.87 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 48.22% | 17.12% | -2.62% | -44.32% |
| Safety | ||||
| Net Debt / EBITDA | 2.28 | 1.35 | 0.58 | 0.23 |
| Interest Coverage | -10.16 | -56.36 | -73.76 | -63.93 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -278.66 | -1,129.42 | -381.33 |